Zolpigen

Quick links to important sections

Zolpigen

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zolpigen

Quick Facts

Property Description
Active ingredient Zolpidem tartrate
Form Tablet (Immediate- and Extended-Release), Sublingual Tablet, Oral Spray
Pharmacological class Sedative-Hypnotic (Z-drug)
Common use Short-term treatment of insomnia
Origin Synthetic imidazo[1,2-a]pyridine compound

Zolpigen is the trade name for a prescription-only medication whose active component is Zolpidem tartrate, a wholly synthetic compound classified as a Sedative-Hypnotic. It is primarily intended for the short-term treatment of insomnia particularly for patients experiencing difficulties falling asleep.

Classification as a Non-Benzodiazepine Receptor Modulator

Zolpidem belongs to the pharmacological subgroup known as Z-drugs, or non-benzodiazepine receptor modulators, a feature that distinguishes it from older sleeping medications. Its unique imidazo[1,2-a]pyridine structure is clinically recognized for providing a selective action in the brain compared to traditional benzodiazepines. The medication works by boosting the effect of the brain's natural inhibitory neurotransmitter, GABA, thereby promoting sedation and facilitating the onset of sleep.

Available Pharmaceutical Forms and Targeted Use

The active ingredient is manufactured into several pharmaceutical preparations to control the drug's delivery and absorption profile. These include the standard oral tablet, the extended-release tablet (designed to assist with both sleep initiation and maintenance), and the sublingual tablet (absorbed rapidly under the tongue). This variety in dosage forms is a key differentiating factor, allowing medical practitioners to select a preparation that best fits the patient’s specific sleep challenge, whether it is primarily with sleep initiation or with sustaining rest.

What side effects are possible with Zolpigen?

Officially Documented Adverse Reactions

The official regulatory documentation for Zolpigen (Zolpidem tartrate) classifies potential adverse reactions based on clinical trial frequency and organ system involvement. Reactions classified as Common (occurring in 1% to 10% of patients in studies) include central nervous system (CNS) effects such as somnolence, headache, and dizziness, alongside gastrointestinal issues like nausea and diarrhea.

Less frequent, Uncommon reactions may involve confusion, aggression, tremor, and blurred vision. The most infrequent categories, Rare and Very Rare, include serious events such as respiratory depression and gait disturbance.

Serious Safety Concerns and Specific Constraints

Official labeling highlights the risk of complex sleep behaviors, which can include actions like sleep-driving or sleepwalking, resulting in amnesia and potential serious injury. Severe hypersensitivity reactions, including anaphylaxis and angioedema (swelling of the tongue or throat), are also documented serious adverse reactions.

Safety is formally constrained in specific patient groups. Zolpigen is contraindicated in patients with conditions like severe hepatic insufficiency, severe obstructive sleep apnoea, and myasthenia gravis. Older adults are noted to have increased sensitivity and risk of falls. Additionally, the official labeling notes that anterograde amnesia occurs most often several hours after ingestion, and rebound insomnia may occur upon abrupt cessation of treatment.

Overdose and Emergency Response

Zolpigen Overdose and When to Seek Help

The official regulatory profile for Zolpigen (Zolpidem tartrate) defines overdose as an exaggeration of the drug's Central Nervous System (CNS) depressant effects, necessitating immediate emergency action.

Overdose Scope (Official Regulatory Findings) Regulator-Mandated Action
Documented Manifestations: Symptoms range from drowsiness, confusion, and lethargy to severe ataxia, decreased consciousness, and potential coma. Overdose may also result in hypotension and life-threatening respiratory depression. Immediate Medical Attention: Contact emergency services without delay if any sign of overdose is suspected. Hospital monitoring and observation are required for management.

The severity of overdose is documented to be substantially increased by the co-ingestion of alcohol or other CNS depressants, which amplifies the risk of fatal outcomes. Official labeling indicates that management is primarily symptomatic and supportive treatment, focused on closely monitoring cardiac and respiratory function. Decontamination procedures like gastric lavage or activated charcoal may be considered. Hemodialysis is ineffective for Zolpidem. Although the reversal agent Flumazenil may be used in specific cases, its administration is associated with the documented risk of inducing convulsions. Special consideration is required for elderly patients and those with hepatic impairment due to increased sensitivity.

Therapeutic Uses of Zolpigen

What Zolpigen Treats: Main Uses and Benefits

Zolpigen is commonly used for the short-term management of insomnia, focusing on symptomatic relief for patients experiencing difficulty falling asleep or maintaining continuous rest. The medication is applied in clinical settings marked by disruptive sleep patterns that interfere with daily stability.

Addressing Difficulty Falling Asleep and Sustaining Rest

The medication generally addresses sleep initiation deficits—the struggle to fall asleep after getting into bed—and, with specific formulations, manages sleep maintenance disruptions such as nocturnal awakenings. It is commonly used to help with reducing the time required for sleep onset (sleep latency) and may assist with reducing the frequency of awakenings, which generally helps ease the overall symptom burden associated with nocturnal sleeplessness.

It is relevant for acute or episodic changes in sleep and may be part of symptomatic management for transient or chronic insomnia.

“The medication is applied in scenarios where additional management of discomfort is required to support the patient during difficult episodes by easing distress.”

Fact Box: Symptom Management

Symptom Cluster Therapeutic Benefit
Sleep Initiation Deficits May assist with reducing time to sleep onset
Nocturnal Awakenings Plays a role in managing the frequency of waking
Non-Restorative Sleep Supports a more consolidated sleep period

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Zolpigen (zolpidem) is primarily intended for the short-term treatment of insomnia in adults. However, it is not safe or appropriate for everyone.

Contraindications

Zolpigen must not be used by individuals who:

  • Have had a prior allergic reaction (e.g., swelling, trouble breathing) to zolpidem or its inactive ingredients.
  • Have experienced complex sleep behaviors (e.g., sleep-driving, sleepwalking) after taking zolpidem.
  • Have severe liver impairment.
Patient Population Precautions & Warnings
Elderly Patients (65+) Increased risk of confusion, dizziness, and falls. A lower starting dose is typically necessary.
Individuals with Respiratory Issues Use with caution in patients with conditions like sleep apnea or chronic obstructive pulmonary disease (COPD), as it can worsen breathing problems.
Pregnancy & Breastfeeding Generally not recommended. Use in the late stages of pregnancy may cause sedation or breathing issues in the newborn.
Mental Health History Use with caution if there is a history of depression, suicidal thoughts, or substance abuse.

It is essential to discuss your complete health history, including any current medications or alcohol use, with your healthcare provider to determine if Zolpigen is right for you.

What should I know about interactions with other medicines?

Formal Restrictions and Contraindications

Co-administration with alcohol is prohibited due to the officially documented risk of additive Central Nervous System (CNS) depressant effects. The medication is also contraindicated in patients with a history of experiencing complex sleep behaviors after taking zolpidem products. Furthermore, Zolpigen is contraindicated in patients with severe hepatic impairment, as noted in regulatory information.

Interactions Affecting Plasma Concentration

The drug's official profile includes pharmacokinetic interactions involving its metabolism by the CYP3A4 enzyme system. Co-administration with potent enzyme inhibitors such as Ketoconazole may increase Zolpigen exposure (Cmax and AUC). Conversely, co-administration with enzyme inducers like Rifampin or the herbal product St. John’s wort may significantly decrease Zolpigen exposure, potentially reducing its expected effect.

Additive CNS Depression

A primary pharmacodynamic interaction is the additive effect observed when Zolpigen is used alongside other CNS depressants, including opioids and sedating medications like certain antipsychotics (e.g., Chlorpromazine) or tricyclic antidepressants (e.g., Imipramine). This combination carries an increased official risk of profound sedation and respiratory depression. Regulatory information also notes that ingesting Zolpigen with or immediately after a meal may decrease peak plasma concentration and slow the time of onset.

Mechanism of Action

Zolpigen functions as a GABA A receptor positive allosteric modulator within the central nervous system (CNS). The drug exhibits a selective affinity for the GABA A receptor subtype that contains the alpha1 subunit. This receptor complex is the primary mediator of inhibitory signaling via the neurotransmitter GABA (gamma-aminobutyric acid).

Zolpigen does not act as an agonist; it does not directly activate the receptor. Instead, its binding to an allosteric site induces a conformational change in the receptor protein. This structural modification enhances the intrinsic affinity of the receptor for GABA. Consequently, when GABA binds, the receptor's integral chloride ion channel opens more frequently or for a longer duration.

This facilitated GABA A receptor activity increases the influx of negatively charged chloride ions into the postsynaptic neuron. The resultant hyperpolarization of the neuronal membrane decreases the cell's excitability. This specific enhancement of inhibitory neurotransmission leads to a widespread, measurable decrease in overall central nervous system activity and associated reduction in arousal state.

Dosage and Administration Information

How to Use Zolpigen

Administration of Zolpigen (zolpidem tartrate) follows standardized protocols concerning route, dose, and timing. The medication is available in multiple forms, including Immediate-Release (IR) and Extended-Release (ER) oral tablets, as well as a sublingual tablet. The primary approved routes are oral and sublingual.

Official Dosing and Frequency

Treatment is intended for short-term use and should generally not exceed four weeks. The medicine is administered as a single dose once per night. The dose must be taken immediately before bedtime or, for the sublingual form, upon waking in the middle of the night.

Population Group Initial Dosing Regimen (IR / ER Tablets) Maximum Dose per Night
Standard Adults (Men) 5 mg or 10 mg / 6.25 mg or 12.5 mg 10 mg (IR) / 12.5 mg (ER)
Standard Adults (Women) 5 mg / 6.25 mg 10 mg (IR) / 12.5 mg (ER)
Older Adults (Geriatric) 5 mg / 6.25 mg 5 mg (IR) / 6.25 mg (ER)

Administration Conditions

All doses must only be taken if the patient has at least 7 to 8 hours of time remaining for sleep before the planned time of awakening. The sublingual tablet requires at least 4 hours of remaining sleep time. Taking the tablet with or immediately after a meal may delay the onset of its effect.

Special handling is required for certain forms: Extended-Release tablets must be swallowed whole and must not be crushed, divided, or chewed. Sublingual tablets must be placed under the tongue and allowed to disintegrate completely.

Recent Clinical Evidence

Zolpigen: Recent Clinical Evidence

Zolpigen (which contains the active ingredient zolpidem) is a non-benzodiazepine sedative-hypnotic agent primarily indicated for the short-term management of insomnia characterized by difficulties with sleep initiation. Clinical studies conducted across various adult populations have investigated its effects on key sleep parameters.

Controlled clinical trials have consistently demonstrated that treatment with zolpidem is associated with a reduction in sleep latency (the time it takes to fall asleep) compared to placebo. This effect has been documented in trials ranging from a few nights up to five weeks of use. In addition to reducing the time to sleep onset, some extended-release formulations and specific doses have been studied for their role in improving sleep maintenance (reducing wake time after sleep onset) in patients with chronic insomnia over periods up to six months.

Key Findings from Randomized Studies

Primary Outcome Measure Observed Effect vs. Placebo (Adults) Duration of Effect Noted
Sleep Latency (Time to fall asleep) Statistically significant decrease Up to 35 days in certain trials
Total Sleep Time Statistically significant increase Variable, with some studies up to 6 months
Wake After Sleep Onset (WASO) Modest or no significant difference observed with immediate-release, improved with some extended-release formulations Variable

Safety and Regulatory Context

It is important to note that regulatory agencies advise the use of zolpidem for a short duration, typically no longer than two to six weeks. Long-term use of sedative-hypnotics may be associated with risks, including dependence, tolerance, and withdrawal symptoms upon abrupt discontinuation. Furthermore, the drug carries a warning regarding the potential for complex sleep behaviors (such as sleepwalking or sleep driving), which have been reported to occur even at recommended doses. Current clinical guidelines generally recommend non-pharmacological treatments, like cognitive behavioral therapy for insomnia (CBT-I), as first-line therapy, with zolpidem reserved as a second-line option for short-term relief.

Frequently Asked Questions (FAQ)

Common questions about Zolpigen (FAQ)

Q: How quickly does Zolpigen typically start working?

Official product information states that Zolpigen is intended for immediate use before bedtime, as it is designed to work quickly. To ensure the intended rapid onset of the sleep effect, label instructions indicate that the medication is generally taken on an empty stomach. Taking it with or right after a meal may significantly slow down how fast the medication begins to work.


Q: What is the usual duration of Zolpigen's effects?

The elimination half-life of the active ingredient, zolpidem, is short, typically around 2.5 hours for a single dose. Regulatory information specifies that the medicine is administered only when the patient has at least 7 to 8 hours of sleep time remaining. This administration condition is designed to mitigate the risk of morning impairment and next-day effects.


Q: Is Zolpigen considered addictive?

Zolpigen is classified by regulatory bodies as a Schedule IV controlled substance. This classification indicates that the medication carries a potential risk of abuse and the development of physical or psychological dependence. For this reason, official prescribing information advises that its use is restricted to a short-term duration.


Q: Are there any over-the-counter medications that interact with Zolpigen?

Official regulatory documents indicate that co-administration of Zolpigen with other medications that cause drowsiness is contraindicated. This includes many over-the-counter sleep aids, certain cold or allergy medicines, and herbal supplements like St. John's Wort. Combining these products can lead to an additive effect, increasing the risk of profound sedation and impaired coordination.


Q: What is the difference between Zolpigen and other common sleep aids?

Zolpigen is a non-benzodiazepine receptor modulator, also commonly referred to as a Z-drug. This classification means its chemical structure is distinct from older sedative medications like traditional benzodiazepines. The medication is designed to selectively target the GABA A receptor subtype in the brain to specifically promote the onset of sleep.


Q: Are there any specific foods I should avoid while on Zolpigen?

Official administration conditions indicate that Zolpigen is intended to be taken without food. Taking the immediate-release tablet with or immediately after a meal can reduce the peak concentration of the drug in the blood and delay the time it takes for the sleep effect to begin. Regulatory sources do not list specific foods to avoid, but generally advise avoiding food intake around the time of the dose.


Q: Can children or teenagers use Zolpigen?

Official regulatory documents clearly state that the safety and effectiveness of Zolpigen have not been established in pediatric patients (children and teenagers). The lack of established safety and effectiveness means that Zolpigen is not approved for use in the pediatric population.


Q: Do women experience different side effects from Zolpigen than men?

Studies indicate that women generally clear the drug from their body at a slower rate than men, resulting in higher drug concentrations. This difference led to regulatory recommendations for a lower starting dose for women. This lower dose is intended to reduce the potential risk of higher drug concentration, which may contribute to side effects like next-day driving impairment.


Q: Does Zolpigen help with anxiety?

Zolpigen is indicated only for the short-term treatment of insomnia as authorized by regulatory agencies. It is not approved for or intended to treat anxiety disorders.


Q: Is there a generic version of Zolpigen available?

Yes, the active component of Zolpigen is zolpidem tartrate. The drug is widely available under its official generic name, as well as under other brand names, depending on the dosage form and the country.


Q: Can I take Zolpigen if I have high blood pressure?

High blood pressure, or hypertension, is not listed as a formal contraindication for the use of Zolpigen in official documents. However, clinical trial data has reported both increases and decreases in blood pressure as infrequent or rare adverse events.


Q: What if I forget to take a dose of Zolpigen?

Official patient guidance indicates that a missed dose should be skipped entirely. Patients are cautioned not to take a forgotten dose later in the night or take a double dose to compensate. The next dose should be taken at the usual time the following night.


Q: Does Zolpigen cause weight gain?

Based on official clinical trial data, weight gain is not listed as a common or frequent side effect of Zolpigen. In fact, official documentation has reported weight decrease as a rare adverse event.


Q: Is it normal to feel a metallic taste after taking Zolpigen?

The experience of a bitter or metallic taste in the mouth, or dry mouth, has been reported as a possible side effect of zolpidem in official patient information leaflets.


Q: What if Zolpigen doesn't seem to be working for me?

Regulatory documents advise that if insomnia persists after 7 to 10 days of Zolpigen use, a medical professional must perform a re-evaluation, as persistent insomnia could signal an underlying medical or psychiatric condition.


Q: Is Zolpigen ever prescribed for restless legs syndrome?

Zolpigen is indicated only for the short-term treatment of insomnia as authorized by regulatory agencies. It is not approved for the treatment of restless legs syndrome.


Q: What are the main risks for patients with kidney issues using Zolpigen?

Official pharmacokinetics data suggests that kidney (renal) impairment generally does not significantly alter how Zolpigen is processed by the body. Therefore, the data suggests that dose adjustments are usually not required. However, regulatory documents advise that patients with kidney issues should still be monitored closely.


Q: What should I do if I think I'm having a severe reaction to Zolpigen?

Official patient safety guidance emphasizes that emergency medical attention must be sought immediately if a patient suspects a severe allergic reaction. This includes symptoms such as difficulty breathing or swelling of the face, tongue, or throat (signs of anaphylaxis or angioedema), as severe hypersensitivity reactions have been reported with this medication.

How should Zolpigen be stored and disposed of?

Zolpigen (Zolpidem tartrate) must be stored and handled according to its official labeled requirements to ensure drug integrity and safety, as it is classified as a Schedule IV controlled substance.

Official Storage and Handling

Requirement Category Official Regulatory Statement
Temperature Requirements Store at controlled room temperature (20 C to 25 C or 68 F to 77 F).
Protection Conditions Must be protected from moisture and dispensed in a tight, light-resistant container.
Container Requirements Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety Keep Zolpigen out of reach of children. Store it in a safe place to prevent misuse and abuse.

Disposal Requirements

Unused or expired Zolpigen must be disposed of according to local regulations. Regulators strongly recommend using authorized drug take-back programs or collection sites. If no take-back program is available, the FDA guidance is to remove the medicine from its container, mix it with an undesirable substance (such as dirt or coffee grounds), and place the mixture in a sealed container before discarding it in the trash. It should not be flushed down a toilet unless explicitly instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zolpigen found in:

A-Z Index: